Leerink Partnrs Has Negative Estimate for Zoetis Q1 Earnings

Zoetis Inc. (NYSE:ZTS) – Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Zoetis in a research note issued to investors on Monday, February 10th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings of $1.43 per share for the quarter, down from their prior forecast of $1.49. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Leerink Partnrs also issued estimates for Zoetis’ Q2 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.64 EPS, Q4 2025 earnings at $1.49 EPS, FY2025 earnings at $6.19 EPS, FY2026 earnings at $6.96 EPS, FY2027 earnings at $7.62 EPS and FY2028 earnings at $8.31 EPS.

Several other analysts have also recently weighed in on the stock. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Morgan Stanley cut their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, Piper Sandler decreased their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $214.00.

Zoetis Price Performance

Shares of ZTS stock opened at $173.99 on Tuesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm has a market cap of $78.50 billion, a P/E ratio of 32.70, a P/E/G ratio of 2.77 and a beta of 0.90. The business’s 50 day moving average price is $169.11 and its 200-day moving average price is $179.11. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.15%. Zoetis’s dividend payout ratio is currently 37.59%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zoetis

A number of hedge funds have recently bought and sold shares of ZTS. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services purchased a new stake in Zoetis in the third quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the 3rd quarter worth approximately $33,000. Dunhill Financial LLC raised its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. Finally, Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.